Drug Trial Radar · NCT07032727
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Sep 12, 2025
Primary completion
Jun 1, 2027
Study completion Jun 1, 2029
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Rigel Pharmaceuticals
- First posted
- Jun 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.
Conditions
- Targeted Therapy
- IDH1-Mutated Malignancies
- Mutations
Interventions
OlutasidenibDrug
Given by po
Cladribine (CLAD)Drug
Given by IV
VenetoclaxDrug
Given by po
GilteritinibDrug
Given by po
RuxolitinibDrug
Given by po
CytarabineDrug
Given SQ
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and adverse events (AEs)Time frame: Through study completion; an average of 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Miami
Miami, Florida · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.